New Zealand reclassifies low-dose CBD medical products, effects yet to be seen

Low-dose CBD products can now be supplied in New Zealand by registered pharmacists without a prescription after the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) reclassified CBD from a prescription-only medicine to a restricted (pharmacist-only) medicine.

The change came as something of a surprise following on from the Ministry of Health asking for feedback on adjusting the minimum quality standard for medical cannabis in August without much explanation.

Read full article
I'm already a subscriber

Fernanda Tucunduva

Legal analyst
Fernanda holds a masters degree in Criminology from the Universitat Pompeu Fabra in Barcelona, Spain. She graduated in Law from de Pontifícia Universidade Católica and specialised in Criminal Corporate Law in São Paulo, Brazil. She has worked as a criminal and compliance lawyer in several law firms and also as an intern in the public sector in Brazil.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization